ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

1Centre for Haematology, Imperial College London, London, England, United Kingdom, 2University of Southampton, Southhampton, England, United Kingdom, 3University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom, 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom, 5Guy's & St. Thomas' NHS Foundation Trust, London, England, United Kingdom, 6The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, London, England, United Kingdom, 7BioMarin Pharmaceutical Inc., Novato, California, United States, 8BioMarin Pharmaceutical, Inc., Novato, California, United States, 9Independent, La Jolla, California, United States

Abstract Number: OC 21.2

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia Gene Therapy

Background: Sustained clinical benefit was demonstrated up to 5 years following a single 6E13 vg/kg dose of valoctocogene roxaparvovec (AAV5-hFVIII-SQ), an investigational gene therapy for severe hemophilia A, in a Phase 1/2 trial (NCT02576795). All 7 participants showed sustained improvements in factor FVIII (FVIII) activity, annualized treated bleeding rate, and use of exogenous FVIII. Similar results were seen for up to 4 years in the 6 participants who received a 4E13 vg/kg dose. No participants chose to resume FVIII prophylaxis. Although these results indicate that valoctocogene roxaparvovec provides substantial hemostatic efficacy, longer follow-up is needed to monitor safety and determine how long the transgene will produce FVIII and protect against bleeding.

Aims: To report safety and efficacy of valoctocogene roxaparvovec up to 6 years after administration in a Phase 1/2 trial.

Methods: Adult male participants with severe hemophilia A who had previously been treated with FVIII received a single intravenous dose of valoctocogene roxaparvovec at 6E13 vg/kg (n=7) or 4E13 vg/kg (n=6).

Results: Updated, detailed safety and efficacy assessments from 6-year follow-up data from the 6E13 vg/kg cohort and 5-year follow-up data from the 4E13 vg/kg cohort will be shared at the ISTH 2022 Congress. Presented endpoints will include summary and individual participant FVIII activity, annualized treated bleeding and FVIII utilization rates, details of bleeding events, and adverse events.

Conclusion(s): The 6-year data from this Phase 1/2 study of valoctocogene roxaparvovec reported at ISTH 2022 will provide the most up-to-date, long-term follow-up data currently available for investigational use of AAV-mediated therapy for hemophilia A. Funded by BioMarin Pharmaceutical Inc.

To cite this abstract in AMA style:

Laffan M, Rangarajan S, Lester W, Symington E, Madan B, Hart D, Li M, Robinson T, Pierce G, Wong W. Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A [abstract]. https://abstracts.isth.org/abstract/hemostatic-results-for-up-to-6-years-following-treatment-with-valoctocogene-roxaparvovec-an-aav5-hfviii-sq-gene-therapy-for-severe-hemophilia-a/. Accessed November 30, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/hemostatic-results-for-up-to-6-years-following-treatment-with-valoctocogene-roxaparvovec-an-aav5-hfviii-sq-gene-therapy-for-severe-hemophilia-a/